Literature DB >> 10759404

Oncolytic viruses.

J Nemunaitis1.   

Abstract

Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been limited to injection site pain, transient fever and tumor necrosis. Responses with early crude materials were usually short in duration; however, recent trials with gene attenuated viruses suggest more prolonged duration to responses observed.

Entities:  

Mesh:

Year:  1999        PMID: 10759404     DOI: 10.1023/a:1006334404767

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.651


  111 in total

1.  In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.

Authors:  M Toda; R L Martuza; H Kojima; S D Rabkin
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

2.  Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity.

Authors:  A T Jamieson; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1974-09       Impact factor: 3.891

3.  [Prolonged spontaneous remission of chronic lymphoid leukemia].

Authors:  J Bousser; R Zittoun
Journal:  Nouv Rev Fr Hematol       Date:  1965 May-Jun

4.  Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer.

Authors:  R J Bensadoun; J C Franquin; G Ciais; V Darcourt; M M Schubert; M Viot; J Dejou; C Tardieu; K Benezery; T D Nguyen; Y Laudoyer; O Dassonville; G Poissonnet; J Vallicioni; A Thyss; M Hamdi; P Chauvel; F Demard
Journal:  Support Care Cancer       Date:  1999-07       Impact factor: 3.603

5.  Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus.

Authors:  S J Russell; A Brandenburger; C L Flemming; M K Collins; J Rommelaere
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity.

Authors:  S K Hoover; S K Barrett; T M Turk; T C Lee; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray; H S Phillips
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

8.  Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1.

Authors:  W W Jia; M McDermott; J Goldie; M Cynader; J Tan; F Tufaro
Journal:  J Natl Cancer Inst       Date:  1994-08-17       Impact factor: 13.506

9.  An adenovirus vector for gene transfer into neurons and glia in the brain.

Authors:  G Le Gal La Salle; J J Robert; S Berrard; V Ridoux; L D Stratford-Perricaudet; M Perricaudet; J Mallet
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

10.  Prevention of syngeneic tumor growth in vaccinia virus-primed mice by immunization with vaccinia virus-modulated tumor cells.

Authors:  K S Wu; S Ueda; Y Sakaue; Y Ohashi; K Ikuta; T Sugano; S Kato
Journal:  Biken J       Date:  1981-12
View more
  7 in total

1.  VP2 capsid domain of the H-1 parvovirus determines susceptibility of human cancer cells to H-1 viral infection.

Authors:  I-R Cho; S Kaowinn; J Song; S Kim; S S Koh; H-Y Kang; N-C Ha; K H Lee; H-S Jun; Y-H Chung
Journal:  Cancer Gene Ther       Date:  2015-04-10       Impact factor: 5.987

2.  Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

Authors:  Marianne M Stanford; John W Barrett; Steven H Nazarian; Steven Werden; Grant McFadden
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

3.  STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.

Authors:  Christina M Ulane; Jason J Rodriguez; Jean-Patrick Parisien; Curt M Horvath
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 4.  In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Authors:  Linda Hammerich; Adam Binder; Joshua D Brody
Journal:  Mol Oncol       Date:  2015-11-10       Impact factor: 6.603

Review 5.  Developments in Intralesional Therapy for Metastatic Melanoma.

Authors:  Sarah Sloot; Omar M Rashid; Arnod A Sarnaik; Jonathan S Zager
Journal:  Cancer Control       Date:  2016-01       Impact factor: 3.302

6.  Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases.

Authors:  P O Vorobyev; F E Babaeva; A V Panova; J Shakiba; S K Kravchenko; A V Soboleva; A V Lipatova
Journal:  Mol Biol       Date:  2022-10-05       Impact factor: 1.540

Review 7.  Gene therapy for lung cancer.

Authors:  Eric B Haura; Eduardo Sotomayor; Scott J Antonia
Journal:  Mol Biotechnol       Date:  2003-10       Impact factor: 2.860

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.